Zimbabwe
Tuberculosis profile
| High TB burden | High HIV burden |
Population  2013 14 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 5.7 (3.6–7.4) 40 (25–52)
Mortality (HIV+TB only) 22 (17–27) 153 (121–189)
Prevalence  (includes HIV+TB) 58 (33–89) 409 (235–630)
Incidence  (includes HIV+TB) 78 (67–91) 552 (474–643)
Incidence (HIV+TB only) 56 (48–66) 395 (341–464)
Case detection, all forms (%) 42 (36–49)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 1.9 (1–3.3) 8.3 (1.8–23)
MDR-TB cases among notified pulmonary
TB cases
520 (270–900) 300 (66–820)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 11 404   1 275
Pulmonary, clinically diagnosed 15 807    
Extrapulmonary 4 413    
       
Total new and relapse 32 899    
Previously treated, excluding relapses 2 379    
Total cases notified 35 278    
Among 32 899 new and relapse cases:
2 567 (8%) cases aged under 15 years; male:female ratio: 1.3
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB     4 276
Laboratory-confirmed RR-/MDR-TB cases     433
Patients started on MDR-TB treatment     351
TB/HIV 2013 Number (%)
TB patients with known HIV status 32 460 (92)
HIV-positive TB patients 22 442 (69)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 17 267 (77)
HIV-positive TB patients on antiretroviral therapy (ART) 17 267 (77)
HIV-positive people screened for TB 323 431  
HIV-positive people provided with IPT 10 926  
Treatment success rate (%)
New cases registered in 2012 81
Previously treated cases registered in 2012  
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011 81
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 1.5
Culture (per 5 million population) 0.7
Drug susceptibility testing (per 5 million population) 0.7
Sites performing Xpert MTB/RIF 58
Is second-line drug susceptibility testing available? Yes, in and outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) 31
% Funded domestically 2%
% Funded internationally 43%
% Unfunded 55%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-03-30 Data: www.who.int/tb/data